ClearAlpha Technologies LP Buys 12,612 Shares of Amedisys, Inc. (NASDAQ:AMED)

ClearAlpha Technologies LP lifted its stake in Amedisys, Inc. (NASDAQ:AMED) by 19.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 77,861 shares of the health services provider’s stock after purchasing an additional 12,612 shares during the period. Amedisys accounts for 2.1% of ClearAlpha Technologies LP’s portfolio, making the stock its 10th largest position. ClearAlpha Technologies LP’s holdings in Amedisys were worth $7,514,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Alpine Associates Management Inc. boosted its stake in shares of Amedisys by 0.9% in the 2nd quarter. Alpine Associates Management Inc. now owns 1,280,897 shares of the health services provider’s stock valued at $117,586,000 after purchasing an additional 11,000 shares during the last quarter. Westchester Capital Management LLC lifted its stake in shares of Amedisys by 9.5% in the 3rd quarter. Westchester Capital Management LLC now owns 1,118,802 shares of the health services provider’s stock valued at $107,976,000 after purchasing an additional 97,476 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Amedisys by 4.0% during the second quarter. Dimensional Fund Advisors LP now owns 514,166 shares of the health services provider’s stock worth $47,202,000 after purchasing an additional 19,660 shares during the period. Calamos Advisors LLC grew its stake in shares of Amedisys by 11.6% during the second quarter. Calamos Advisors LLC now owns 397,347 shares of the health services provider’s stock worth $36,476,000 after purchasing an additional 41,220 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in Amedisys by 2.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider’s stock valued at $33,400,000 after purchasing an additional 9,004 shares during the last quarter. Institutional investors own 94.36% of the company’s stock.

Amedisys Price Performance

Shares of AMED opened at $91.41 on Monday. The stock has a market cap of $2.99 billion, a P/E ratio of 36.27, a price-to-earnings-growth ratio of 1.92 and a beta of 0.78. Amedisys, Inc. has a 1 year low of $88.81 and a 1 year high of $98.95. The stock’s 50-day moving average price is $94.74 and its two-hundred day moving average price is $95.62. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Wednesday, November 6th. The health services provider reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.19). The firm had revenue of $587.67 million for the quarter, compared to analyst estimates of $586.75 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The firm’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.98 EPS. On average, equities analysts predict that Amedisys, Inc. will post 4.55 earnings per share for the current year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.